Participant Flow



Baseline Characteristics*

	Treatment arm		
	Gremubamab 1500mg (n=12)	**Gremubamab 500mg (n=13)**	**Placebo (n=12)**
Age	65 (53-79)	58 (52-69)	72 (60-75)
Female at birth	8 (67%)	11 (85%)	8 (67%)
Inhaled antibiotics	6 (50%)	5 (39%)	3 (25%)
Smoking History			
Current	0 (0%)	1 (8%)	2 (17%)
Ex	6 (50%)	4 (31%)	3 (25%)
Never	6 (50%)	8 (61%)	7 (58%)
FEV1 % predicted	74.3 (62.0-87.0)	62.0 (53.0-70.6)	57.2 (45.8-70.0)
BSI			
0-4	3 (25%)	5 (38%)	6 (50%)
5-8	4 (33%)	4 (31%)	2 (17%)
9+	5 (42%)	4 (31%)	4 (33%)
Exacerbations in previous year			
0	3 (25%)	1 (8%)	2 (17%)
1-2	6 (50%)	6 (46%)	4 (33%)
3+	3 (25%)	6 (46%)	6 (50%)

** Median and inter-quartile range for continuous data, number and percentage for categorical data.*
FEV1: Forced expiratory volume in the first second.
BSI: Bronchiectasis Severity Index.

Outcome measures

Primary endpoint: Change from baseline (day 1) in P. aeruginosa bacterial burden in sputum at week 12 (day 84), assessed by quantitative sputum cultures (colony-forming units (CFU)). All data are log_{10}-transformed.

	Treatment arm		
	Gremubamab 1500mg	**Gremubamab 500mg**	**Placebo**
Baseline (Day 1)*$	7.16 (1.53) [n=12; 1 below LLoD]	8.56 (0.76) [n=13; all above LLoD]	7.55 (1.76) [n=12; all above LLoD]
Week 12 (Day 84)*$	6.93 (1.70) [n=12; 1 below LLoD]	7.02 (2.08) [n=13; 2 below LLoD]	7.72 (2.05) [n=12; 1 below LLoD]
Change from baseline*$	-0.23 (2.13) [n=12]	-1.54 (1.94) [n=13]	0.18 (1.85) [n=12]
Main analysis: Adjusted mean difference in change from baseline vs Placebo†$	-0.66 95% CI: (-1.71, 0.39) 1-sided p = 0.208	-1.25 95% CI: (-2.33, -0.16) 1-sided p = 0.0710	NA
Sensitivity analysis: Adjusted mean difference in change from baseline vs Placebo†¶	-0.67 95% CI: (-1.76, 0.43) 1-sided p = 0.215	-1.28 95% CI: (-2.41, -0.15) 1-sided p = 0.0738	NA

** Presented as mean (standard deviation) [number of observations (n); number of observations below LLoD].*

$ Undetectable levels of CFU/g were imputed with the assay LLoD, i.e. log_{10}-CFU/g = log_{10}(1000).

¶ Undetectable levels of CFU/g were imputed with half the assay LLoD, i.e. log_{10}-CFU/g = log_{10}(500).

† Adjusted for randomised treatment arm, baseline log_{10}-CFU/g, long-term antibiotic use at baseline, and site (random effect).

CI: Confidence interval.

LLoD: Lower limit of detection.

CFU: Colony-forming units

Adverse Events

Number of patients with at least one Adverse Event and Serious Adverse Event per arm.

Treatment arm	Number of patients	Number with at least one AE	Number with one or more (at least possibly treatment related) AE	Number with at least one SAE	Number with one or more (at least possibly treatment related) SAE
Gremubamab 1500mg	12	11 (91.7%)	7 (58.3%)	0 (0.0%)	0 (0.0%)
Gremubamab 500mg	13	11 (84.6%)	8 (61.5%)	2 (15.4%)	1 (7.7%)
Placebo	12	11 (91.7%)	5 (41.7%)	2 (16.7%)	0 (0.0%)
Total	**37**	**33 (89.2%)**	**20 (54.1%)**	**4 (10.8%)**	**1 (2.7%)**

Number of patients experiencing Adverse Events by arm. Adverse Events are restricted to those experienced by at least 10% of safety population patients in any arm. All Adverse Events are included, regardless of relationship to treatment.

	Treatment arm		
	Gremubamab 1500mg (n=12)	Gremubamab 500mg (n=13)	Placebo (n=12)
Breathlessness	0 (0.0%)	0 (0.0%)	2 (16.7%)
COVID-19	2 (16.7%)	0 (0.0%)	1 (8.3%)
Cough increased	0 (0.0%)	0 (0.0%)	2 (16.7%)
Fall	2 (16.7%)	1 (7.7%)	0 (0.0%)
Fatigue	1 (8.3%)	2 (15.4%)	1 (8.3%)
Headache	6 (50.0%)	3 (23.1%)	4 (33.3%)
Infective exacerbation of bronchiectasis	0 (0.0%)	2 (15.4%)	2 (16.7%)
Nausea	2 (16.7%)	2 (15.4%)	0 (0.0%)
Sputum increased	0 (0.0%)	0 (0.0%)	2 (16.7%)